PSMD10 and neoplasm: However, the gankyrin-knockdown and SB328437-treated 786-O-PR groups with pazopanib treatment exhibited reduced tumor growth compared with that obtained with the pazopanib-treated and naive 786-O-PR groups (Fig. 6a, b).